United Therapeutics Corporation

UTHR | NASDAQ

Price Alert Chart Builder DCF Calculator

$598.72

+$5.18 (+0.87%)

At close: Oct 30, 2026, 4:00 PM ET

$598.72

$0.00 (0.00%)

After-hours: Oct 30, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.87%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

71.5

-3.5 pts

Fundamentals Excellent

Market Sentiment Neutral

Moat Wide

Sector Rank #49/1028 (Top 5%)

Full Analysis

Key Statistics

Market Data

Market Cap $25.68B

1D Range

593.57 608.69

52W Range

437.33 608.69

Valuation (TTM)

PE 21.45

PB 4.01

EV/EBITDA 13.93

Valuation (NTM)

Forward PE 16.86

Forward PEG -6.65

Price Target $673.67

Cash Flow

FCF Yield 4.3%

SBC Adj. FCF Yield 3.6%

SBC Impact -14.2%

Margins

Gross Margin 86.1%

Operating Margin 44.5%

FCF Margin 34.6%

Growth (CAGR)

Revenue 3Y | 5Y 14.3% | 14.7%

Dil EPS 3Y | 5Y 16.4% | 22.1%

FCF 3Y | 5Y 17.5% | 14.3%

Returns

ROA 18.2%

ROE 20.2%

ROIC 17.7%

Financial Health

Net Cash

$2.66B

Current Ratio 5.73

Interest Coverage 116.95

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-t...

Sector Healthcare

Industry Biotechnology

Employees 1,400

IPO Date Jun 17, 1999

Website www.unither.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · zacks.com

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 days ago · businesswire.com

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors has authorized a new share repurchase program for up to $2 billion of the company's common stock, available through October 21, 2027. “We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling invest.

12 days ago · businesswire.com

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast.

13 days ago · businesswire.com

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.

20 days ago · businesswire.com

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc.

24 days ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

1 month ago · zacks.com

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

1 month ago · benzinga.com

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

1 month ago · zacks.com

United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.